Lung tumors hijack nerves to starve the body

Introduction: a quarter of cancer deaths, a cause long misunderstood

A quiet but devastating syndrome

Cachexia affects roughly half of cancer patients and is believed to account for a quarter of all deaths linked to the disease, according to the Cleveland Clinic. This syndrome causes severe loss of muscle and fat, reduces quality of life, and sometimes even limits the treatment options available to patients.

A study published on July 2, 2026 in the journal Science, led by researcher Thales Papagiannakopoulos, at the time at the NYU Grossman School of Medicine and now an incoming professor at the Salk Institute, reveals an unsuspected mechanism behind this phenomenon: certain lung tumors communicate directly with the brain to trigger this muscle wasting, a finding that overturns decades of assumptions built almost entirely on general nutritional theories of cancer decline.

Why this discovery changes things

Until now, cachexia was mostly understood as a general metabolic consequence of cancer. This new research instead demonstrates a direct dialogue between certain tumors and the peripheral nervous system, opening the door to targeted treatments far more precise than the general nutritional approaches used until now, and forcing clinicians to reconsider how they explain sudden, unexplained weight loss to worried families.

Claim 1: tumors communicate directly with the brain

An unprecedented signaling mechanism

According to the study published in Science, certain lung tumors use a lipid signaling molecule called prostaglandin E2, or PGE2, to communicate with sensory neurons located directly in the lung, which then relay this signal to the brain.

This specific subtype of lung cancer produces markedly higher levels of PGE2 than other tumor subtypes, which would explain why some patients develop severe cachexia while others, with comparably sized tumors, do not, a variability that has long puzzled oncologists trying to predict which patients will decline the fastest.

Verdict: confirmed by several converging experiments

Researchers showed that blocking half of the sensory connections between the lungs and the brain, or completely disabling the lung nerves involved, significantly reduced cachexia symptoms in animal models, confirming the causal role of this neural pathway.

Claim 2: diet directly influences the process

The unexpected role of fat and omega-3s

The study shows that mice fed a diet high in fat developed more severe cachexia, while switching to a diet containing only omega-3 fatty acids limited the body's ability to produce PGE2, thereby preventing tumors from using this molecule to communicate with the nervous system.

When mice were genetically modified to no longer produce PGE2, cachexia simply did not develop, a result that confirms the central role of this specific molecule in the entire mechanism observed.

Verdict: confirmed, with concrete nutritional implications

Smaller-scale trials also showed that administering aspirin and ibuprofen, two common anti-inflammatory drugs that reduce prostaglandin production, also prevented the development of cachexia in the mice tested.

Claim 3: this syndrome affects a massive number of patients worldwide

A scale underestimated by the general public

A German study from 2015, cited as a reference in the current work, already estimated that cachexia affected roughly nine million people worldwide, a figure that illustrates the scale of a syndrome that remains largely unknown to the general public compared to other cancer complications.

This scale is partly explained by the fact that cachexia is not limited to lung cancer: it accompanies many serious chronic diseases, although the neural mechanism discovered here appears particularly relevant to certain specific subtypes of lung tumors.

Verdict: confirmed, a global public health issue

The figure of a quarter of cancer deaths attributable to cachexia, put forward by the Cleveland Clinic, places this syndrome among the most significant causes of mortality in oncology, amply justifying the newly focused scientific attention on its precise mechanisms.

Claim 4: blocking this mechanism could become a treatment

A therapeutic avenue still to be validated in humans

Researchers suggest this discovery could pave the way for new treatments specifically targeting the PGE2 signaling pathway or the sensory neurons involved, rather than being limited to the general nutritional approaches currently used to manage cachexia in cancer patients.

Lead researcher Thales Papagiannakopoulos says he wants to precisely identify which neurons and which brain circuits are involved, before exploring whether these same circuits also play a role in other symptoms frequently reported by cancer patients, such as depression or memory loss.

Verdict: promising but still at the preclinical stage

All of these findings currently come from animal models, and no human clinical trial has yet been conducted to validate the efficacy or safety of an intervention targeting this specific neural pathway in lung cancer patients.

Claim 5: this research mobilized a broad scientific network

A collaboration between several leading institutions

The study was conducted with the participation of researchers from the NYU Grossman School of Medicine, the Salk Institute, Harvard, Rutgers University, Princeton, Cold Spring Harbor, and several other leading American institutions, with financial support from the National Institutes of Health, underscoring how much coordinated public investment was required to trace a single molecular signal across so many disciplines.

This collaborative scale reflects the complexity of the subject studied, which combines expertise in oncology, neuroscience, and metabolism, three fields that rarely communicate this closely in traditional cancer research.

Verdict: a serious and transparent scientific effort

Publication in a journal as rigorously peer-reviewed as Science, with complete methodological data and clearly documented institutional funding, lends solid credibility to this study's conclusions, despite its still-preclinical limitations.

Claim 6: other cancer symptoms may share this neural origin

A lead toward depression and memory loss in patients

Beyond cachexia alone, researchers are now wondering whether the same neural circuits hijacked by lung tumors might also be involved in other symptoms frequently reported by cancer patients, notably depression and memory disorders.

Postdoctoral researcher Stefan Kotschi, a co-author of the study, notes that precisely identifying these neurons and their brain connections could open a much broader window into how a tumor affects the entire body, far beyond weight loss alone.

Verdict: a serious hypothesis, still to be confirmed

This potential extension of the discovery remains, at this stage, a hypothesis for future research rather than an established result, but it illustrates the scale of the possible consequences of a better understanding of the dialogue between tumors and the nervous system.

What this discovery does not yet allow us to claim

Limits that must absolutely be respected

This study does not demonstrate that all lung cancers cause cachexia through this same precise mechanism, nor that the results obtained in mice will automatically transfer, without adaptation, to human patients, an essential caution in preclinical research.

Nor does it allow us to claim that a simple dietary change, such as adopting an omega-3-rich diet, would by itself be enough to treat cachexia in patients already affected, without specialized and individualized medical guidance.

Necessary caution against media enthusiasm

It would be irresponsible to present this discovery as an immediately available treatment, when the researchers themselves stress the need for further research to precisely identify the exact neural circuits involved in humans.

This scientific honesty, far from diminishing the value of the discovery, is instead the best guarantee of long-term credibility for patients who hope to one day benefit from treatments derived from this work.

Conclusion: an advance that redefines our understanding of cancer

A new bridge between neuroscience and oncology

This discovery illustrates just how porous the boundary between neuroscience and oncology is becoming, opening research prospects that would have seemed improbable just a decade ago in treating the most aggressive lung cancers.

Measured hope for the future of patients

If the next stages of research confirm the possibility of therapeutically targeting this signaling pathway in humans, millions of patients worldwide could one day benefit from treatments capable of preserving their muscle mass during their fight against cancer, a real hope that still needs to be clinically confirmed in the years ahead.

By Maxime Marquette, columnist

Columnist's transparency note

Who I am and how I work

I am a columnist, not an oncologist or neuroscience researcher. My analysis relies exclusively on the scientific publication in Science and the official press release from the Salk Institute, without any personal medical interpretation beyond what the authors themselves state.

My limits and my acknowledged biases

My editorial angle favors measured science communication and realistic hope, never promising an imminent treatment. I cannot guarantee that results obtained in animals will be replicated in humans, and I encourage any concerned patient to consult their medical team rather than draw personal conclusions from this article.

Sources

Primary sources

Salk Institute — Are lung cancer tumors hijacking the nervous system? — July 2, 2026

Science — A dietary switch promotes sensory-neuron dependent cancer-associated cachexia — July 2, 2026

Secondary sources

Cleveland Clinic — Cachexia, causes and prevalence in cancer

ecancer — Researchers find way to treat lung cancer and associated muscle wasting at the same time — July 2026

PMC — Oncology Letters, review on cancer cachexia

Nature — tumor-nervous system signaling in cancer